A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
In order to study the growth kinetics of breast tumours during long-term hormonal withdrawal, we developed a transplantable, invasive mammary carcinoma EMR-86 that originated in a female WAG/Olac rat bearing a subcutaneously implanted oestrogen pellet (EP). Outgrowth of transplanted tumours occurs only in the presence of an EP, and metastases are formed in lungs and regional lymph nodes. Subsequent EP removal induces rapid regression. However, tumours do not disappear completely, as small nodules persist. These dormant tumour remnants can be restimulated even after long periods. Because EP-stimulated tumours regressed after treatment with bromocriptine and dormant tumours in non-oestrogenized rats grew out after treatment with perphenazine, prolactin is the major growth-stimulating hormone in this model. Cell kinetics in the growing, regressing and dormant phase were studied by immunocytochemical detection of DNA-incorporated bromodeoxyuridine (BrdUrd) in tissue sections. BrdUrd labelling indices decreased from 21.6 +/- 3.0% to less than 1% within 7 days after EP removal. After prolonged hormonal withdrawal (up to 90 days) BrdUrd-labelled tumour cells could always be demonstrated (range 0.4-0.8%), without a concomitant increase in tumour volume. Additional treatment either with bromocriptine or with ovariectomy could not significantly reduce this residual proliferative activity, as demonstrated by continuous BrdUrd labelling experiments. The results indicate that in vivo dormancy may represent a steady state of cell division and cell loss, rather than an accumulation of cells in a non-cycling G0 state.
Wijsman
J H
JH
Department of Surgery, University Hospital, Leiden, The Netherlands.
Cornelisse
C J
CJ
Keijzer
R
R
van de Velde
C J
CJ
van Dierendonck
J H
JH
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis; D004343:Drug Implants; D004958:Estradiol / Q000097:blood / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D008325:Mammary Neoplasms, Experimental / Q000473:pathology*; D009362:Neoplasm Metastasis; D009365:Neoplasm Regression, Spontaneous; D009368:Neoplasm Transplantation; D010546:Perphenazine / Q000494:pharmacology; D011003:Ploidies; D011388:Prolactin / Q000097:blood / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains
D004273:DNA, Neoplasm; D004343:Drug Implants; D001971:Bromocriptine; D004958:Estradiol; D011388:Prolactin; D010546:Perphenazine